

II. 2001 CFSAN Program Priorities

FDA is requesting comments concerning the establishment of program priorities in CFSAN for FY 2001. The input will be used to develop CFSAN's 2001 workplan. The workplan will set forth the Center's program priorities for October 1, 2000, through September 30, 2001. FDA intends to make the 2001 workplan available in October 2000.

The format of the 2001 workplan will be similar to the 2000 workplan. Moreover, FDA expects there will be considerable continuity between the 2000 and 2001 workplans. For example, a broad program area targeted for enhancement in the 2000 plan is improving the safety of imported food; five specific activities are identified to implement the Imported Foods Action Plan. As the initiative to prevent importation of unsafe food requires a multiyear effort, ensuring the safety of imported food will continue to be a high priority in the 2001 workplan. The same is true for the Egg Safety Action Plan. FDA requests comments on other broad program areas that should continue to be a priority in FY 2001.

In addition, because the 2000 workplan, as noted above, was a condensed (i.e., 9-month) plan, our goal for FY 2000 will be to fully complete at least three-quarters of the "A" list activities. FDA requests comments on those "A" list activities in the 2000 plan that, if not completed, should be carried over to the 2001 workplan. FDA also requests comments on the FY 2000 "B" list activities that should be elevated to the "A" list for completion in FY 2001. Finally, FDA requests comments on new program areas or activities that should be a high priority for FY 2001.

Interested persons may submit to the Dockets Management Branch (address above) written comments regarding this notice by August 25, 2000. Two copies of any comments are to be submitted, except that individuals may submit one copy. Comments are to be identified with the docket number found in brackets in the heading of this document. Received comments may be seen in the office between 9 a.m. and 4 p.m., Monday through Friday.

Dated: June 19, 2000.

Margaret M. Dotzel,

Associate Commissioner for Policy.

[FR Doc. 00-16067 Filed 6-23-00; 8:45 am]

BILLING CODE 4160-01-F

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration

Medical Imaging Drugs Advisory Committee; Notice of Meeting

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice.

This notice announces a forthcoming meeting of a public advisory committee of the Food and Drug Administration (FDA). The meeting will be open to the public.

Name of Committee: Medical Imaging Drugs Advisory Committee.

General Function of the Committee: To provide advice and recommendations to the agency on FDA's regulatory issues.

Date and Time: The meeting will be held on July 10, 2000, 8:30 a.m. to 5:30 p.m.

Location: Holiday Inn, Versailles Ballrooms I and II, 8120 Wisconsin Ave., Bethesda, MD.

Contact Person: Thomas H. Perez, Center for Drug Evaluation and Research (HFD-21), Food and Drug Administration, 5600 Fishers Lane, Rockville, MD 20857, 301-827-6758, e-mail at PerezT@cder.fda.gov, or FDA Advisory Committee Information Line, 1-800-741-8138 (301-443-0572 in the Washington, DC area), code 12540. Please call the Information Line for up-to-date information on this meeting.

Agenda: The committee will discuss biologic license application (BLA) 99-1407, Leutech™ (Technetium labeled TC99m anti/CD15 antibody injection), Palatin Technologies, Inc., imaging agent as an aid in the diagnosis of equivocal appendicitis.

Procedure: Interested persons may present data, information, or views, orally or in writing, on issues pending before the committee. Written submissions may be made to the contact person by July 3, 2000. Oral presentations from the public will be scheduled between approximately 1 p.m. and 2 p.m. Time allotted for each presentation may be limited. Those desiring to make formal oral presentations should notify the contact person before July 3, 2000, and submit a brief statement of the general nature of the evidence or arguments they wish to present, the names and addresses of proposed participants, and an indication of the approximate time requested to make their presentation.

Notice of this meeting is given under the Federal Advisory Committee Act (5 U.S.C. app. 2).

Dated: June 19, 2000.

Linda A. Suydam,

Senior Associate Commissioner.

[FR Doc. 00-16065 Filed 6-23-00; 8:45 am]

BILLING CODE 4160-01-F

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Health Care Financing Administration

[Document Identifier: HCFA-R-0282]

Agency Information Collection Activities: Proposed Collection; Comment Request

AGENCY: Health Care Financing Administration.

In compliance with the requirement of section 3506(c)(2)(A) of the Paperwork Reduction Act of 1995, the Health Care Financing Administration (HCFA), Department of Health and Human Services, is publishing the following summary of proposed collections for public comment. Interested persons are invited to send comments regarding this burden estimate or any other aspect of this collection of information, including any of the following subjects: (1) The necessity and utility of the proposed information collection for the proper performance of the agency's functions; (2) the accuracy of the estimated burden; (3) ways to enhance the quality, utility, and clarity of the information to be collected; and (4) the use of automated collection techniques or other forms of information technology to minimize the information collection burden.

Type of Information Request: Reinstatement, without change, of a previously approved collection; *Title of Information Collection:* Medicare+Choice (M+C) Organization Appeals and Grievance Data Disclosure Requirements and Supporting Regulations in 42 CFR 422.64, 422.111, and 422.560-422.622; *HCFA Form Number:* HCFA-R-0282 (OMB approval #: 0938-0778); *Use:* These information collection pertains to the aggregate number and disposition of grievances and appeals by M+C organizations. Both the Balanced Budget Act (BBA) of 1997 and the Government Performance and Results Act (GPRA) of 1993 establish a need for HCFA to set and monitor performance standards in the area of appeals. The purpose is to hold M+C organizations accountable to regulators and consumers, as well as promote informed choice; *Frequency:* Semi-annually; *Affected Public:* Business or other for-profit; *Number of Respondents:* 268; *Total Annual*